ARCA Biopharma Announces AB201 Development Program For Treatment of COVID-19 Associated Coagulopathy - Colorado Bioscience Association

This topic is empty.

Viewing 1 post (of 1 total)

Author

Posts
05/28/2020 at 12:07 pm #5335

Colorado BioScience Association
Keymaster

ARCA biopharma, Inc. (Nasdaq: ABIO) today announced a new development program to evaluate AB201 (rNAPc2), a potent, selective inhibitor of tissue factor (TF), as a potential treatment for COVID-19 associated coagulopathy (CAC) and the related inflammatory response.

Learn more.
Author

Posts

Viewing 1 post (of 1 total)

You must be logged in to reply to this topic.